Quick Answer
Verrica Pharmaceuticals Inc. reported Net Income Loss of -$17.89 million for the year ending 2025.
- Verrica Pharmaceuticals Inc. showed an increase of +76.6% in Net Income Loss from 2024 to 2025.
- This data is from Verrica Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), Verrica Pharmaceuticals Inc.'s Net Income Loss has declined by 301.1%.
- Historical annual values: Fiscal year 2025: -$17.89 million | Fiscal year 2024: -$76.58 million | Fiscal year 2023: -$67.00 million | Fiscal year 2022: -$24.49 million | Fiscal year 2021: -$35.08 million | Fiscal year 2020: -$42.69 million | Fiscal year 2019: -$28.21 million | Fiscal year 2018: -$20.65 million | Fiscal year 2017: -$4.46 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: